Huateng Pharmaceutical, a global supplier of pharmaceutical intermediates & chemical products & biological reagent & PEG derivatives, offers Plerixafor, CAS NO.110078-46-1 for your requirements of R&D, evaluation, pilots and commercial along with supportive technical package required for evaluation.

Application: Plerixafor, CAS NO.110078-46-1 is a hematopoietic stem cell (HSC) mobilizer that inhibits the CXCR4 chemokine receptor and blocks binding of its ligand, stromal cell-derived factor-1-α (SDF-1-α). This agent was approved on Dec. 15, 2008, as treatment in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Selective CXCR4 antagonist.